BR9910071A - Composição farmacêutica, processos para aumentar e manter a homogeneidade de uma composição farmacêutica e para tratar, reverter, reduzir ou inibir infecções retrovirais, uso de abacavir, lamivudina, zidovudina ou de um derivado farmaceuticamente aceitável dos mesmos, e de um agente de deslizamento farmaceuticamente aceitável, artigo de manufatura, e, processo para a preparação de uma composição farmacêutica - Google Patents

Composição farmacêutica, processos para aumentar e manter a homogeneidade de uma composição farmacêutica e para tratar, reverter, reduzir ou inibir infecções retrovirais, uso de abacavir, lamivudina, zidovudina ou de um derivado farmaceuticamente aceitável dos mesmos, e de um agente de deslizamento farmaceuticamente aceitável, artigo de manufatura, e, processo para a preparação de uma composição farmacêutica

Info

Publication number: BR9910071A
Authority: BR; Brazil
Prior art keywords: pharmaceutical composition; pharmaceutically acceptable; abacavir; lamivudine; zidovudine
Prior art date: 1998-04-29

Application number

BR9910071-1A

Other languages

English (en)

Portuguese (pt)

Inventor

Robin Currie

Sunil Jain

Allen Wayne Wood

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-29

Filing date

1999-04-26

Publication date

2000-12-26

1999-04-26 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2000-12-26 Publication of BR9910071A publication Critical patent/BR9910071A/pt

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 7
238000000034 method Methods 0.000 title abstract 6
229960004748 abacavir Drugs 0.000 title abstract 3
MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 title abstract 3
229960001627 lamivudine Drugs 0.000 title abstract 3
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 title abstract 3
229960002555 zidovudine Drugs 0.000 title abstract 3
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 title abstract 3
206010038997 Retroviral infections Diseases 0.000 title abstract 2
230000002401 inhibitory effect Effects 0.000 title abstract 2
238000004519 manufacturing process Methods 0.000 title abstract 2
241000725303 Human immunodeficiency virus Species 0.000 abstract 2
230000000840 anti-viral effect Effects 0.000 abstract 2
238000009795 derivation Methods 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Inorganic Chemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Biophysics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BR9910071-1A 1998-04-29 1999-04-26 Composição farmacêutica, processos para aumentar e manter a homogeneidade de uma composição farmacêutica e para tratar, reverter, reduzir ou inibir infecções retrovirais, uso de abacavir, lamivudina, zidovudina ou de um derivado farmaceuticamente aceitável dos mesmos, e de um agente de deslizamento farmaceuticamente aceitável, artigo de manufatura, e, processo para a preparação de uma composição farmacêutica BR9910071A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9809213.3A GB9809213D0 (en)	1998-04-29	1998-04-29	Pharmaceutical compositions
PCT/EP1999/002794 WO1999055372A1 (en)	1998-04-29	1999-04-26	Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine

Publications (1)

Publication Number	Publication Date
BR9910071A true BR9910071A (pt)	2000-12-26

Family

ID=10831228

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9910071-1A BR9910071A (pt)	1998-04-29	1999-04-26	Composição farmacêutica, processos para aumentar e manter a homogeneidade de uma composição farmacêutica e para tratar, reverter, reduzir ou inibir infecções retrovirais, uso de abacavir, lamivudina, zidovudina ou de um derivado farmaceuticamente aceitável dos mesmos, e de um agente de deslizamento farmaceuticamente aceitável, artigo de manufatura, e, processo para a preparação de uma composição farmacêutica

Country Status (23)

Country	Link
EP (1)	EP1083932A1 (id)
JP (1)	JP2002512979A (id)
KR (1)	KR20010043128A (id)
CN (1)	CN1411380A (id)
AP (1)	AP2000001971A0 (id)
AU (1)	AU4135599A (id)
BR (1)	BR9910071A (id)
CA (1)	CA2330391A1 (id)
EA (1)	EA200000997A1 (id)
EE (1)	EE200000646A (id)
GB (1)	GB9809213D0 (id)
HR (1)	HRP20000732A2 (id)
HU (1)	HUP0101622A3 (id)
ID (1)	ID26955A (id)
IL (1)	IL139181A0 (id)
IS (1)	IS5675A (id)
NO (1)	NO20005418L (id)
NZ (1)	NZ507745A (id)
PL (1)	PL343710A1 (id)
SK (1)	SK16212000A3 (id)
TR (1)	TR200003157T2 (id)
WO (1)	WO1999055372A1 (id)
ZA (1)	ZA200005922B (id)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6875773B1 (en)	1998-05-29	2005-04-05	Ben M. Dunn	Combination therapy for treatment of FIV infection
CA2374198A1 (en) *	1998-05-29	1999-12-02	Maki Arai	Combination therapy for treatment of fiv infection
GB9820417D0 (en) *	1998-09-18	1998-11-11	Glaxo Group Ltd	Antiviral combinations
US7074417B2 (en) *	2000-10-13	2006-07-11	Advancis Pharmaceutical Corporation	Multiple-delayed release anti-viral product, use and formulation thereof
AU2002311622A1 (en) *	2002-04-23	2003-11-10	Lupin Limited	Long acting compositions comprising zidovudine and lamivudine
AR040242A1 (es) *	2002-06-04	2005-03-23	Glaxo Group Ltd	Composiciones farmaceuticas
CN100335125C (zh) *	2003-06-03	2007-09-05	上海现代药物制剂工程研究中心	杀毒抗菌用长效干扰素喷鼻粉剂
WO2006114709A1 (en) *	2005-04-25	2006-11-02	Aurobindo Pharma Limited	Pharmaceutical compositions of antiretrovirals
WO2007013047A2 (en) *	2005-07-29	2007-02-01	Ranbaxy Laboratories Limited	Water-dispersible anti-retroviral pharmaceutical compositions
ES2279707B1 (es) *	2005-11-10	2008-06-01	Combino Pharm, S.L.	Formulaciones orales que comprenden 3'-azidonucleosidos.
BRPI0816498A2 (pt) *	2007-10-02	2019-02-26	Emory University	combinações potentes de zidovudina e drogas que selecionam para a mutuação k65r na polimerase do hiv
US20110117193A1 (en) *	2008-01-17	2011-05-19	Duquesne University Of The Holy Spirit	Antiretroviral drug formulations for treatment of children exposed to hiv/aids
PE20121524A1 (es) *	2010-01-27	2012-12-03	Viiv Healthcare Co	Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos
CN114010776A (zh)	2010-06-09	2022-02-08	疫苗技术股份有限公司	用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
IN2014MN01907A (id)	2012-03-05	2015-07-10	Cipla Ltd
CA2885763C (en)	2012-10-23	2021-04-06	Cipla Limited	Pharmaceutical antiretroviral composition
SG10201910773VA (en)	2013-06-13	2020-01-30	Akebia Therapeutics Inc	Compositions and methods for treating anemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY115461A (en) *	1995-03-30	2003-06-30	Wellcome Found	Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9622681D0 (en) *	1996-10-31	1997-01-08	Glaxo Group Ltd	Pharmaceutical compositions

1998
- 1998-04-29 GB GBGB9809213.3A patent/GB9809213D0/en not_active Ceased
1999
- 1999-04-26 HU HU0101622A patent/HUP0101622A3/hu unknown
- 1999-04-26 NZ NZ507745A patent/NZ507745A/en unknown
- 1999-04-26 KR KR1020007012021A patent/KR20010043128A/ko not_active Withdrawn
- 1999-04-26 HR HR20000732A patent/HRP20000732A2/hr not_active Application Discontinuation
- 1999-04-26 BR BR9910071-1A patent/BR9910071A/pt not_active IP Right Cessation
- 1999-04-26 JP JP2000545569A patent/JP2002512979A/ja active Pending
- 1999-04-26 WO PCT/EP1999/002794 patent/WO1999055372A1/en not_active Ceased
- 1999-04-26 TR TR2000/03157T patent/TR200003157T2/xx unknown
- 1999-04-26 SK SK1621-2000A patent/SK16212000A3/sk unknown
- 1999-04-26 IL IL13918199A patent/IL139181A0/xx unknown
- 1999-04-26 EE EEP200000646A patent/EE200000646A/xx unknown
- 1999-04-26 CN CN99807983A patent/CN1411380A/zh active Pending
- 1999-04-26 ID IDW20002479A patent/ID26955A/id unknown
- 1999-04-26 AU AU41355/99A patent/AU4135599A/en not_active Abandoned
- 1999-04-26 CA CA002330391A patent/CA2330391A1/en not_active Abandoned
- 1999-04-26 AP APAP/P/2000/001971A patent/AP2000001971A0/en unknown
- 1999-04-26 EP EP99924822A patent/EP1083932A1/en not_active Withdrawn
- 1999-04-26 EA EA200000997A patent/EA200000997A1/ru unknown
- 1999-04-26 PL PL99343710A patent/PL343710A1/xx unknown
2000
- 2000-10-20 IS IS5675A patent/IS5675A/is unknown
- 2000-10-23 ZA ZA200005922A patent/ZA200005922B/xx unknown
- 2000-10-27 NO NO20005418A patent/NO20005418L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ZA200005922B (en)	2001-10-23
JP2002512979A (ja)	2002-05-08
CN1411380A (zh)	2003-04-16
AU4135599A (en)	1999-11-16
NO20005418L (no)	2000-11-29
HUP0101622A2 (hu)	2002-03-28
IL139181A0 (en)	2001-11-25
NO20005418D0 (no)	2000-10-27
ID26955A (id)	2001-02-22
AP2000001971A0 (en)	2000-12-31
GB9809213D0 (en)	1998-07-01
HUP0101622A3 (en)	2003-09-29
HRP20000732A2 (en)	2001-02-28
TR200003157T2 (tr)	2001-01-22
PL343710A1 (en)	2001-08-27
CA2330391A1 (en)	1999-11-04
IS5675A (is)	2000-10-20
EP1083932A1 (en)	2001-03-21
KR20010043128A (ko)	2001-05-25
EA200000997A1 (ru)	2001-06-25
NZ507745A (en)	2004-07-30
WO1999055372A1 (en)	1999-11-04
EE200000646A (et)	2002-04-15
SK16212000A3 (sk)	2001-07-10

Similar Documents

Publication	Publication Date	Title
BR9910071A (pt)	2000-12-26	Composição farmacêutica, processos para aumentar e manter a homogeneidade de uma composição farmacêutica e para tratar, reverter, reduzir ou inibir infecções retrovirais, uso de abacavir, lamivudina, zidovudina ou de um derivado farmaceuticamente aceitável dos mesmos, e de um agente de deslizamento farmaceuticamente aceitável, artigo de manufatura, e, processo para a preparação de uma composição farmacêutica
FI20001231A7 (fi)	2000-05-23	2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
BR9813373A (pt)	2000-10-03	Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR9911076A (pt)	2001-02-20	Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
PT80079B (pt)	1987-09-18	Processo para a preparacao de composicoes farmaceuticas anti-virus contendo 2-dietilamino-2',6'-acetoxilida (lidocaina)
CA2293470A1 (en)	1998-12-17	Benzimidazole derivatives
PT100199A (pt)	1993-07-30	Combinacao antiviral de nucleosidos e processo para a sua preparacao
YU7296A (sh)	1998-08-14	Farmaceutska kompozicija koja sadrži kombinaciju jedne protivvirusne supstance i jednog protivzapaljenskog glukokortikoida
KR950002785A (ko)	1995-02-16	골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
BR9811121A (pt)	2000-07-18	Produto, composição farmacêutica, e uso de um produto
MY104575A (en)	1994-04-30	Therapeutic nucleosides.
BRPI0112962B8 (pt)	2021-05-25	composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
EP0293826A3 (en)	1989-05-10	Therapeutic and prophylactic application of sulfated polysaccharides against aids
BR9712614A (pt)	1999-10-26	Composição farmacêutica,processos para aumentar e manter a homogeneidade de uma composição farmac&eutica,para tratar,reverter,reduzir ou inibir infeccões retrovirais e para preparação de uma composição farmacêutica,uso de lamivudina ou de um derivado farmaceuticamenete aceitável da mesma,de zidovudina,ou de um derivado farmaceuticamente aceitável da mesma e de um agente de deslizamento farmaceuticamente aceitável,e, artigo de amnufatura.
KR890003387A (ko)	1989-04-14	국소활성을 갖는 이중-가닥 RMAs조성물
BR9711647A (pt)	2000-06-06	Novos derivados de ácido dicafeoilquìmico, seu uso, composições com os mesmos e métodos de tratamento usando-os.
DK0484112T3 (da)	1995-09-18	Anvendelse af lithium ved behandlingen eller profylakse af Molluscum contagiosum
KR880007080A (ko)	1988-08-26	제약학적 생성물
BR0206775A (pt)	2006-01-17	Uso de um medicamento para tratar um indivìduo infectado com hiv, por combinação de imunização com interrupção estruturada do tratamento anti-retrovirótico
BR9916043A (pt)	2001-12-04	Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes
BR9808060A (pt)	2000-03-08	Composição farmacêutica, processos para tratamento de infecções virais pela administração de uma quantidade farmaceuticamente segura e eficaz de uma composição farmacêutica, uso da lamivudina ou um seu derivado farmaceuticamente aceitável, e, processo para a preparação de uma composição farmacêutica.
MY105855A (en)	1995-02-28	Therapeutic nucleotides.
PT99057A (pt)	1992-08-31	Processo para a preparacao de composicoes farmaceuticas contendo uma mistura sinergica de glicoproteina cd4 da superficie das ceelulas ou de um seu analogo com um agente polianionico anti-hiv, nomeadamente um polissacarido sulfatado
ES2101850T3 (es)	1997-07-16	Composicion topica que potencia la curacion de lesiones de herpes.
DE68900760D1 (de)	1992-03-05	Virushemmende nukleosidmischung.

Legal Events

Date	Code	Title	Description
2007-08-21	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.
2011-12-13	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.